Prostate-Specific Antigen Screening and Mortality from Prostate Cancer

Department of Epidemiology, UMDNJ-School of Public Health, Piscataway, NJ 08854, USA.
Journal of General Internal Medicine (Impact Factor: 3.42). 04/2008; 23(3):248-53. DOI: 10.1007/s11606-007-0479-7
Source: PubMed


There is no available evidence from randomized trials that early detection of prostate cancer improves health outcomes, but the prostate-specific antigen (PSA) test is commonly used to screen men for prostate cancer.
The objective of the study is to see if screening with PSA decreases mortality from prostate cancer.
This is a case-control study using one-to-one matching on race, age, and time of availability of exposure to PSA screening. Decedents, 380, from New Jersey Vital Statistics 1997 to 2000 inclusive, 55-79 years of age at diagnosis were matched to living controls without metastatic prostate cancer. Medical records were obtained from all providers, and we abstracted information about PSA tests from 1989 to the time of diagnosis in each index case.
Measurements consist of a comparison of screening (yes, no) between cases and controls. Measure of association was the odds ratio.
Eligible cases were diagnosed each year from 1989 to 1999 with the median year being 1993. PSA screening was evident in 23.2-29.2% of cases and 21.8-26.1% of controls depending on the screening criteria. The unadjusted, matched odds ratio for dying of prostate cancer if ever screened was 1.09 (95% CI 0.76 to 1.60) for the most restrictive criteria and 1.19 (95% CI, 0.85 to 1.66) for the least restrictive. Adjustment for comorbidity and education level made no significant differences in these values. There were no significant interactions by age or race.
PSA screening using an ever/never tabulation for tests from 1989 until 2000 did not protect New Jersey men from prostate cancer mortality.

Download full-text


Available from: Stephen W Marcella, Jun 13, 2015
6 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Various organic and inorganic compounds have been identified to be very effective arc interrupters when applied to the silver elements of high power current limiting fuses (typical ratings for a single barrel range from 5.5-15.5 kV, 20-250 Amps). These compounds reduced the noninterruption band which occurs between the rated fuse current and the minimum interruption current. The lower current limit at which the fuse can interrupt is directly affected by the gases evolved during arcing. These new compounds generate gases and free radicals which assist in deionizing the arc by a combination of the gas species evolved, increased local pressure, and by not forming any carbon residues. These novel compounds and binders significantly improved the interruption capability of high power fuses at low current levels. Compounds, test methods, evaluation, actual short circuit tests in a high power lab, and theoretical analysis are described
    IEEE Transactions on Power Delivery 02/1995; DOI:10.1109/61.368391 · 1.73 Impact Factor
  • Source
    The Lancet 05/1997; 349(9059):1180. DOI:10.1016/S0140-6736(05)63066-8 · 45.22 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Prostate cancer is the most common nonskin cancer in men in the United States, and prostate cancer screening has increased in recent years. In 2002, the U.S. Preventive Services Task Force concluded that evidence was insufficient to recommend for or against screening for prostate cancer with prostate-specific antigen (PSA) testing. To examine new evidence on benefits and harms of screening asymptomatic men for prostate cancer with PSA. English-language articles identified in PubMed and the Cochrane Library (search dates, January 2002 to July 2007), reference lists of retrieved articles, and expert suggestions. Randomized, controlled trials and meta-analyses of PSA screening and cross-sectional and cohort studies of screening harms and of the natural history of screening-detected cancer were selected to answer the following questions: Does screening for prostate cancer with PSA, as a single-threshold test or as a function of multiple tests over time, decrease morbidity or mortality? What are the magnitude and nature of harms associated with prostate cancer screening, other than overtreatment? What is the natural history of PSA-detected, nonpalpable, localized prostate cancer? Studies were reviewed, abstracted, and rated for quality by using predefined U.S. Preventive Services Task Force criteria. No good-quality randomized, controlled trials of screening for prostate cancer have been completed. In 1 cross-sectional and 2 prospective cohort studies of fair to good quality, false-positive PSA screening results caused psychological adverse effects for up to 1 year after the test. The natural history of PSA-detected prostate cancer is poorly understood. Few eligible studies were identified. Long-term adverse effects of false-positive PSA screening test results are unknown. Prostate-specific antigen screening is associated with psychological harms, and its potential benefits remain uncertain.
    Annals of internal medicine 09/2008; 149(3):192-9. · 17.81 Impact Factor
Show more